Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

  • Home
  • /
  • Sotac Pharmaceutical
Join Channel
Consolidated Standalone

Sotac Pharmaceutical

₹130.1 0 | 0%

WEBSITE BSE:0 NSE : 17 May, 00:00

Market Cap ₹144 Cr.

Stock P/E 42.2

P/B 3.2

Current Price ₹130.1

Book Value ₹ 41

Face Value 10

52W High ₹155

Dividend Yield 0%

52W Low ₹ 97

Edit Ratio

Sotac Pharmaceutical Research see more...

Overview Inc. Year: 2015Industry: Pharmaceuticals & Drugs

Sotac Pharmaceuticals Limited is a leading pharmaceutical manufacturer in India. The company specializes in manufacturing a wide range of pharmaceutical products, including Non Beta-Lactam (general) tablets, Non Beta-Lactam (general) capsules, oral liquid, dry syrup, and external preparations such as ointments, lotions, and creams.As part of the SOTAC Group, based in Gujarat, Sotac Pharmaceuticals caters to a diverse clientele on a loan license or contract manufacturing basis. Their goal is to become one of the country’s leading manufacturers and development services providers in both the international and domestic markets. The company’s therapeutic portfolio covers a wide spectrum, including anti-diabetic, anti-psychotic, vitamins, minerals, iron, anti-cold, anti-allergic, derma products, antacid, anti-ulcerants, PPI, anti-emetics, cardiac, anti-hypertensives, analgesic, anti-pyretic, anti-inflammatory, anti-bacterial, anti-viral, general antibiotics (IP-Lactams & Non-IP-Lactams), and anti-fungal medications.

Read More..

Sotac Pharmaceutical Share Price

New

₹ | |

Volume
Price

Quarterly Price

Quarterly Monthly
Show Value Show %

Peer Comparison

Sotac Pharmaceutical Quarterly Results

#(Fig in Cr.) Jun 2022 Dec 2022 Jun 2023 Dec 2023
Net Sales 20 20 25 26
Other Income 0 0 0 1
Total Income 20 20 25 26
Total Expenditure 18 18 23 23
Operating Profit 2 2 3 4
Interest 0 0 0 1
Depreciation 1 1 1 1
Exceptional Income / Expenses 0 0 0 -0
Profit Before Tax 1 1 2 1
Provision for Tax 1 0 1 1
Profit After Tax 1 1 1 1
Adjustments 0 -0 0 0
Profit After Adjustments 1 1 1 1
Adjusted Earnings Per Share 0.7 0.7 0.9 0.8

Sotac Pharmaceutical Profit & Loss

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
Net Sales 29 49 73 77 91
Other Income 0 0 0 0 1
Total Income 29 49 73 78 91
Total Expenditure 27 47 67 70 82
Operating Profit 2 2 6 8 11
Interest 0 1 1 2 1
Depreciation 1 3 1 2 4
Exceptional Income / Expenses 0 0 0 1 0
Profit Before Tax 0 -2 5 4 5
Provision for Tax 0 0 2 2 3
Profit After Tax 0 -2 3 2 4
Adjustments 0 0 0 0 0
Profit After Adjustments 0 -2 3 2 4
Adjusted Earnings Per Share 0.1 -2.9 3.6 2.8 3.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 5% 38% 0% 0%
Operating Profit CAGR 33% 59% 0% 0%
PAT CAGR -33% 0% 0% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR 5% NA% NA% NA%
ROE Average 28% 2% 2% 2%
ROCE Average 22% 16% 13% 13%

Sotac Pharmaceutical Balance Sheet

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023
Shareholder's Funds 3 2 7 19
Minority's Interest 2 0 0 0
Borrowings 6 9 1 8
Other Non-Current Liabilities 0 0 0 0
Total Current Liabilities 19 23 28 46
Total Liabilities 30 35 35 74
Fixed Assets 16 17 9 26
Other Non-Current Assets 1 1 1 1
Total Current Assets 14 17 26 47
Total Assets 30 35 35 74

Sotac Pharmaceutical Cash Flow

#(Fig in Cr.) Mar 2020 Mar 2021 Mar 2022 Mar 2023
Opening Cash & Cash Equivalents 1 0 0 0
Cash Flow from Operating Activities 0 -0 6 8
Cash Flow from Investing Activities -12 -3 -4 -12
Cash Flow from Financing Activities 11 3 -3 13
Net Cash Inflow / Outflow -0 -0 0 10
Closing Cash & Cash Equivalent 0 0 0 10

Sotac Pharmaceutical Ratios

# Mar 2020 Mar 2021 Mar 2022 Mar 2023
Earnings Per Share (Rs) 0.11 -2.94 3.58 2.84
CEPS(Rs) 1.85 0.28 4.98 5.67
DPS(Rs) 0 0 2 0
Book NAV/Share(Rs) 3.8 3.1 8.23 12.41
Core EBITDA Margin(%) 6.53 2.98 8.44 9.44
EBIT Margin(%) 2.41 -2.11 7.2 7.7
Pre Tax Margin(%) 1.25 -4.21 6.42 5.07
PAT Margin (%) 0.31 -4.84 3.94 2.95
Cash Profit Margin (%) 5.2 0.47 5.48 5.89
ROA(%) 0.29 -7.27 8.23 4.2
ROE(%) 2.86 -85.23 63.16 27.53
ROCE(%) 4.18 -5.71 31.31 21.5
Receivable days 88.82 47.99 45.25 64.05
Inventory Days 29.65 26.72 25.51 44.84
Payable days 193.78 112.91 106.65 143.83
PER(x) 0 0 0 0
Price/Book(x) 0 0 0 0
Dividend Yield(%) 0 0 0 0
EV/Net Sales(x) 0.54 0.39 0.13 0.26
EV/Core EBITDA(x) 7.33 12.26 1.51 2.66
Net Sales Growth(%) 0 70.76 49.77 5.92
EBIT Growth(%) 0 -249.43 610.65 13.37
PAT Growth(%) 0 -2803.31 221.7 -20.58
EPS Growth(%) 0 -2803.31 221.7 -20.58
Debt/Equity(x) 4.4 6.87 1.12 2.21
Current Ratio(x) 0.71 0.76 0.94 1.03
Quick Ratio(x) 0.59 0.55 0.74 0.73
Interest Cover(x) 2.07 -1.01 9.24 2.92
Total Debt/Mcap(x) 0 0 0 0

Sotac Pharmaceutical Shareholding Pattern

# Sep 2023 Mar 2024
Promoter 72.85 72.85
FII 8.51 8.99
DII 0 0
Public 18.64 18.16
Others 0 0
Total 100 100

Pros

Cons

  • Company has a low return on equity of 2% over the last 3 years.
  • Debtor days have increased from 106.65 to 143.83days.
  • Stock is trading at 3.2 times its book value.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Sotac Pharmaceutical News

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares

Please Login!

Click to Login
OR
Get free Account

Error!